La Wallonie octroie 15 millions à iTeos
La Wallonie octroie 15 millions – iTeos
Read Post
Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD
Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD Leriglitazone (MIN-102), a novel, brain penetrant, orally bioavailable and selective PPARγ agonist, is currently in late-stage development for treatment of severe orphan CNS disorders, including X-ALD and Friedreich’s Ataxia. It previously received Orphan Drug Designation from EMA and FDA for both […]
Read Post
Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science
Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science Mont-Saint Guibert, Belgium, 4 December, 2019: Novadip Biosciences (“Novadip” or “the company”), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces that it is presenting data in a series […]
Read Post
Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia
Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and selective PPARγ agonist Second Orphan Drug Designation granted by the European Commission for leriglitazone, in addition to X-linked adrenoleukodystrophy (X-ALD) Orphan Drug Status provides a number of […]
Read Post
Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS
Notice of Business Alliance between Promethera® Biosciences SA and MEDIPAL HOLDINGS – Bringing Innovative Liver-Focused Cell Therapies to Japanese Markets – Promethera® Biosciences SA (“Promethera®“) and MEDIPAL HOLDINGS CORPORATION (“MEDIPAL”) today announced that they have entered into a business alliance agreement. In conjunction with today’s alliance, MEDIPAL has decided to increase its shareholdings in the […]
Read Post
EyeD Pharma CEO Melanie Mestdagt in the news
EyeD Pharma CEO Melanie Mestdagt in the news
Read Post
Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia
Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and selective PPARγ agonist Second Orphan Drug Designation granted by the FDA for leriglitazone in addition to X-linked adrenoleukodystrophy (X-ALD) Potential for seven years of marketing exclusivity in the USA upon approval in […]
Read Post
Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson
Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson SAN DIEGO, Oct. 15, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamar Howson, a highly seasoned life sciences executive, […]
Read Post
Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis – Milestone Achieved Nine Months Ahead of Initial Schedule; Top-Line Data Expected in Q3 2020 – SAN DIEGO, Oct. 10, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, […]
Read Post
Minoryx: Un axe Espagne-Belgique pour sauter la barrière
Minoryx News Article: Un axe Espagne-Belgique pour sauter la barrière
Read Post
Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia
Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia Recruitment of 39 patients in multicenter European phase 2 trial completed ahead of schedule Mataró, Barcelona, Spain and Charleroi, Belgium, October 8, 2019 – Minoryx Therapeutics, a company specializing in the development of innovative treatments for orphan central nervous system […]
Read Post
Novadip Biosciences – Belgische ‘biotechplasticine’ redt been vijfjarige
Novadip Press Article: Belgische ‘biotechplasticine’ redt been vijfjarige
Read Post
Novadip Biosciences Presents Clinical Case Study on Next Generation Tissue Regeneration Therapy for Critical Size Bone Reconstruction at EORS Conference
Novadip Biosciences Presents Clinical Case Study on Next Generation Tissue Regeneration Therapy for Critical Size Bone Reconstruction at EORS Conference Study highlights potential benefit in rare pediatric orthopedic disorder Mont-Saint-Guibert, Belgium, October 2, 2019: Novadip Biosciences (“Novadip” or “the company”), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple […]
Read Post
FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019
FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019 Ghent, Belgium, 23 September 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in […]
Read Post
Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist
Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist SAN DIEGO, Sept. 18, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced dosing of the first healthy […]
Read Post
Immunic, Inc.’s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range
Immunic, Inc.’s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range – Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dose – – […]
Read Post
Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds
Ghent, Belgium, and Dresden, Germany – 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine ConfoBodyTM-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library for the discovery of small molecule GPCR-modulating compounds. Under the terms […]
Read Post
Confo Therapeutics receives €1.7 million grant from VLAIO
Ghent, Belgium, 20 June 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the Company’s proprietary pre-clinical programs, targeting a neurological orphan indication. The grant will […]
Read Post
First patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia
Mataró, Barcelona, Spain and Charleroi, Belgium, June 4, 2019- Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has been dosed with its lead candidate, leriglitazone (MIN102), in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia. This first patient was dosed at the […]
Read Post
Safety and immune stimulation data from an intranodal delivery of TriMix mRNA
Safety and immune stimulation data from an intranodal delivery of TriMix mRNA, in the adjuvant melanoma study E011-MEL Niel (Belgium), 1 June 2019 – eTheRNA immunotherapies NV (Niel, Belgium) announces that Dr. Ana Arance, Medical Oncologist at Hospital Clinic de Barcelona, will present safety and immune response data from the E011-MEL study at the ASCO […]
Read Post
Appointment of Chief Financial Officer
Niel (Belgium), 29 May 2019 – eTheRNA immunotherapies NV, the mRNA immunotherapy company, is pleased to announce the appointment of Ulrich Platte as the Company’s Chief Financial Officer. Ulrich will join the company on 3rd June 2019. Ulrich has a broad experience acquired over the last 20 years in different industries including the life sciences, […]
Read Post
Novadip presents data at 30th annual EURAPS Research Council Meeting
Novadip Biosciences presents data at 30th annual EURAPS Research Council Meeting Data demonstrates safety and efficacy of allogenic 3D scaffold-free tissue engineered product for deep thickness skin regeneration Mont-Saint Guibert, Belgium, 23 May 2019: Novadip Biosciences (“Novadip”), a regenerative medicine company and pioneer in the development of three-dimensional tissue products derived from adipose stem cells […]
Read Post
EyeD Pharma successfully raises €28 million
Fund+, Qbic and a number of respected Belgian entrepreneurs have placed their trust in EyeD Pharma, a Liège-based pharmaceutical company. Its exceptional fundraising of €28 million will enable progress in the development and production of innovative therapeutic solutions in ophthalmology, particularly for the treatment of glaucoma. Liège, 20 May 2019 – EyeD Pharma was created […]
Read Post
Confo Therapeutics raises €30 million in Series A financing
Round led by BioGeneration Ventures and co-led by Wellington Partners, with investments by Fund+, Perceptive Advisors and existing investors Ghent, Belgium, 7 May 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the completion of a €30 million ($33.4 million) Series A financing. The investment was led by BioGeneration Ventures (BGV) and co-led […]
Read Post